PMEL and neoplasm: This bispecific fusion protein composed of a soluble affinity-enhanced TCR and an anti-CD3 scFv, targets tumor cells that express a peptide of Gp-100 presented by HLA*A0201, creating an immune synapse that kills targeted tumor cells (Middleton et al., 2020).